文献速递妇科

卵巢癌中胚系与体细胞BRCA检测的时间模式及采用情况

Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer.
PubMed 文献 · Obstet Gynecol · 2022-10-05

基于真实世界数据库的横断面研究纳入2011年1月1日至2018年11月30日诊断的2557例卵巢癌患者,72.2%至少接受过一次BRCA检测,其中62.5%仅胚系检测、10.6%仅体细胞检测、19.9%两者均做。诊断后1年内检测比例从2011年24.6%升至2018年75.6%,但仍有较多患者未检测。

要点

  • 2557例卵巢癌患者中72.2%至少有一次BRCA检测记录。
  • 检测者中62.5%仅胚系、10.6%仅体细胞、19.9%两者均做。
  • 诊断后1年内BRCA检测比例从2011年24.6%升至2018年75.6%。

核心结论

  • 在大型卵巢癌队列中,可操作BRCA突变的检测存在显著实践差异,尽管检测率随时间上升,许多患者仍未接受检测,提示错失靶向治疗和遗传咨询的机会。

研究设计与样本

  • 横断面研究,纳入真实世界数据库中2011年1月1日至2018年11月30日诊断的成人卵巢癌患者,接受一线治疗且随访至少1年,共2557例。

主要发现

  • 2557例患者中72.2%(n=1,846)至少有一次BRCA检测记录。
  • 检测患者中62.5%(n=1,154)仅胚系检测,10.6%(n=197)仅体细胞检测,19.9%(n=368)两者均做。
  • 9.7%(n=276)在一线治疗前检测,48.6%(n=1,521)在一线治疗期间检测,17.6%(n=273)在二线治疗期间检测,12.7%(n=129)在三线治疗期间检测。
  • 接受BRCA检测者较未检测者更年轻(平均年龄63岁 vs 66岁,P<.001),更可能在学术机构接受治疗(10.4% vs 7.0%,P=.01),并按ECOG体能评分(P<.001)、疾病分期(P<.001)、组织学(P<.001)、地理区域(P<.001)和一线治疗类型(P<.001)存在差异,种族或民族无差异。
  • 诊断后1年内接受BRCA检测的比例从2011年24.6%上升至2018年75.6%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To describe the testing rate, patient characteristics, temporal trends, timing, and results of germline and somatic BRCA testing in patients with ovarian cancer using real-world data. METHODS: We included a cross-sectional subset of adult patients diagnosed with ovarian cancer between January 1, 2011, and November 30, 2018, who received frontline treatment and were followed for at least 1 year in a real-world database. The primary outcome was receipt of BRCA testing, classified by biosample source as germline (blood or saliva) or somatic (tissue). Lines of therapy (frontline, second line, third line) were derived based on dates of surgery and chemotherapy. Descriptive statistics were analyzed. RESULTS: Among 2,557 patients, 72.2% (n=1,846) had at least one documented BRCA test. Among tested patients, 62.5% (n=1,154) had only germline testing, 10.6% (n=197) had only somatic testing, and 19.9% (n=368) had both. Most patients had testing before (9.7%, n=276) or during (48.6%, n=1,521) frontline therapy, with 17.6% (n=273) tested during second-line and 12.7% (n=129) tested during third-line therapy. Patients who received BRCA testing, compared with patients without testing, were younger (mean age 63 years vs 66 years, P <.001) and were more likely to be treated at an academic practice (10.4% vs 7.0%, P =.01), with differences by Eastern Cooperative Oncology Group performance score ( P <.001), stage of disease ( P <.001), histology ( P <.001), geography ( P <.001), and type of frontline therapy ( P <.001), but no differences based on race or ethnicity. The proportion of patients who received BRCA testing within 1 year of diagnosis increased from 24.6% of patients in 2011 to 75.6% of patients in 2018. CONCLUSION: In a large cohort of patients with ovarian cancer, significant practice disparities existed in testing for actionable BRCA mutations. Despite increased testing over time, many patients did not receive testing, suggesting missed opportunities to identify patients appropriate for targeted therapy and genetic counseling.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Huepenbecker SP, Wright JD, Downer MK, et al. Temporal Patterns and Adoption of Germline and Somatic BRCA Testing in Ovarian Cancer. Obstet Gynecol. 2022. PMID: 36201776. doi:10.1097/AOG.0000000000004958

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。